Abstract: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.

Abstract: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.

Abstract: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.

Abstract: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.

Abstract: The invention relates to a medicament for preventing and/or treating schizophrenia which comprises as an active ingredient cilostazol or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a diagnostic agent for eating disorders comprising as an active ingredient an antibody against brain-derived neurotrophic factor, and a method for detecting eating disorders comprising measuring of the concentration of a brain-derived neurotrophic factor in blood. Particularly, the eating disorders can easily be diagnosed by measuring the concentration of a brain-derived neurotrophic factor in blood of the patients with an antibody against brain-derived neurotrophic factor and a labeled antibody against brain-derived neurotrophic factor.

Abstract: The invention relates to a medicament for preventing and/or treating schizophrenia which comprises as an active ingredient cilostazol or a pharmaceutically acceptable salt thereof.

Abstract: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.

Abstract: The present invention provides a diagnostic agent for eating disorders comprising as an active ingredient an antibody against brain-derived neurotrophic factor, and a method for detecting eating disorders comprising measuring of the concentration of a brain-derived neurotrophic factor in blood. Particularly, the eating disorders can easily be diagnosed by measuring the concentration of a brain-derived neurotrophic factor in blood of the patients with an antibody against brain-derived neurotrophic factor and a labeled antibody against brain-derived neurotrophic factor.

Abstract: The present invention relates to a method of examining or diagnosing schizophrenia, which includes measuring concentrations of D-serine and L-serine in a biological sample. According to the method of the present invention, schizophrenia can be examined or diagnosed by measuring concentrations of D-serine and L-serine in a biological sample by analysis techniques such as high performance liquid chromatography and the like.

Abstract: The present invention relates to N-alkylpiperidine derivatives represented by general formula (1) or (2); wherein R1 represents optionally fluorinated lower alkyl; R2 represents lower alkyl; and R3 represents alkenyl substituted at the 1-position with hydroxy, lower alkoxy, lower alkoxyalkyloxy, lower alkoxyalkyloxyalkyloxy, or lower alkanoyloxy and substituted at the end with radioactive iodine, or alkenyloxymethyl substituted at the end with a radioactive iodine reagent containing the same for assaying central local AchE activity; a method for assaying the central local AchE activity; and labeled precursors of the above compounds. After easily passing through the blood-brain barrier, these compounds are hydrolyzed specifically by AchE in the brain into alcohols, which are then captured by the brain. In contrast, alcohols formed outside the brain do not migrate into the brain. The compounds of the invention emit &ggr;-rays at an appropriate energy level.

Abstract: The present invention relates to N-alkylpiperidine derivatives represented by general formula (1) or (2); 1

Abstract: The present invention relates to N-alkylpiperidine derivatives represented by general formula (1) or (2); wherein R1 represents optionally fluorinated lower alkyl; R2 represents lower alkyl; and R3 represents alkenyl substituted at the 1-position with hydroxy, lower alkoxy, lower alkoxyalkyloxy, lower alkoxyalkyloxyalkyloxy, or lower alkanoyloxy and substituted at the end with radioactive iodine, or alkenyloxymethyl substituted at the end with a radioactive iodine reagent containing the same for assaying central local AchE activity; a method for assaying the central local AchE activity; and labeled precursors of the above compounds. After easily passing through the blood-brain barrier, these compounds are hydrolyzed specifically by AchE in the brain into alcohols, which are then captured by the brain. In contrast, alcohols formed outside the brain do not migrate into the brain. The compounds of the invention emit &ggr;-rays at an appropriate energy level.

Abstract: A method for therapeutically treating tardive dyskinesia, which comprises a compound having an enzyme-inhibitory activity against a phospho-diesterase as the active ingredient, is now provided. Rolipram is preferred as the active ingredient. When rolipram is administered to such rats as experimental model, which have tardive dyskinesia induced by consecutive administrations of haloperidol, there can be obtained such curative effect that the symptoms of tardive dyskinesia are suppressed dose-dependently.